SYMBICORT® in the Treatment of COPD

AstraZeneca

Overview

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners

Study Type

OBSERVATIONAL

Conditions

COPD

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * patients (m/f) with COPD (GOLD stadium III and IV) Exclusion Criteria: * patients who recently quit smoking (\<3months)

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.